Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ Mon, 20 Jun 2022 13:49:03 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://parentsofallergicchildren.org/wp-content/uploads/2021/06/icon-5.png Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ 32 32 Three major differences between ruxolitinib and ruxolitinib cream https://parentsofallergicchildren.org/three-major-differences-between-ruxolitinib-and-ruxolitinib-cream/ Mon, 20 Jun 2022 13:49:03 +0000 https://parentsofallergicchildren.org/three-major-differences-between-ruxolitinib-and-ruxolitinib-cream/ Ruxolitinib is a type of targeted oral therapy called a kinase inhibitor and is mainly used to treat conditions such as medium- and high-risk graft versus host disease, erythroblastosis and myelofibrosis, while ruxolitinib cream is a topical dermatological agent that is applied directly to the skin to treat eczema, vitiligo, atopic dermatitis and baldness. Although […]]]>

Ruxolitinib is a type of targeted oral therapy called a kinase inhibitor and is mainly used to treat conditions such as medium- and high-risk graft versus host disease, erythroblastosis and myelofibrosis, while ruxolitinib cream is a topical dermatological agent that is applied directly to the skin to treat eczema, vitiligo, atopic dermatitis and baldness. Although ruxolitinib and ruxolitinib cream are very different from each other, they are easily confused because they have a similar name. Changzhou Pharmaceutical Factory (CPF), one of the leading ruxolitinib suppliers in China, here analyzes the differences between them in terms of three major aspects to help people know more about them.

1. Indication

Ruxolitinib was approved by FDA in November 2011 and European Commission in August 2012 and is a kind of targeted drug with specific indications. It is used to treat patients who suffer from three types of disease, including steroid-refractory acute graft-versus-host disease, erythroblastosis, and moderate to high risk myelofibrosis (MF). But Ruxolitinib cream is in the development stage and fails to hit the market. It is therefore a topical medicine for the treatment of shinbone disease and baldness and does not yet have any approved indications. However, studies have demonstrated the clinical excellence of Ruxolitinib cream in the treatment of vitiligo, atopic dermatitis and severe baldness.

2. How to apply

Ruxolitinib is an oral kinase inhibitor that acts as a small molecule inhibitor of JAK1 and JAK2 protein kinases, and is the first drug approved by the FDA to treat myelofibrosis. But Ruxolitinib cream is a topical application cream which fundamentally differs from Ruxolitinib in the way it is used.

3. Side effect

Ruxolitinib has obvious side effects. The most common hematologic side effects associated with its use are reduced platelet count and anemia, and the most common non-hematologic side effects are petechiae, dizziness, and headache. However, Ruxolitinib cream is still in clinical trials, so its side effects are undetermined.

Media Contact
Company Name: Changzhou Pharmaceutical Factory
E-mail: Send an email
Call: +86 519 88821493
Address:NOPE. 518 East Laodong Road
Town: Changzhou
State: jiangsu
Country: China
Website: https://www.cz-pharma.com/

]]>
The essential news of the week of June 13 https://parentsofallergicchildren.org/the-essential-news-of-the-week-of-june-13/ Fri, 17 Jun 2022 20:10:21 +0000 https://parentsofallergicchildren.org/the-essential-news-of-the-week-of-june-13/ This week’s best articles: FDA authorizes Moderna, Pfizer-BioNTech COVID-19 vaccines for children up to 6 months The FDA today announces the EUA of Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children 6 months of age and older. More than 300 pediatricians submit personal gun violence testimonies to Congressional record Ahead of the US Senate […]]]>

This week’s best articles:

FDA authorizes Moderna, Pfizer-BioNTech COVID-19 vaccines for children up to 6 months

The FDA today announces the EUA of Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children 6 months of age and older.

More than 300 pediatricians submit personal gun violence testimonies to Congressional record

Ahead of the US Senate Judiciary Committee hearing on gun violence prevention, the American Academy of Pediatrics announced the submission of a statement including more than 300 pediatricians sharing their personal testimonies on the topic.

Somapacitan injection once a week shows its effectiveness in children with GHD

Data from a recent study of weekly injection of somapacitan show positive results for prepubertal children with growth hormone deficiency (GHD).

FDA accepts sNDA for review of Myfembree for treatment of uterine fibroids

The FDA recently announced the acceptance of a Supplemental New Drug Application for relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

More articles from this week:

The challenges of prescribing isotretinoin

Scynexis submits an sNDA for the extension of the indication of ibrexafungerp tablets

Comparison of methods for recruiting parents of autistic children

The youth mental health crisis: supporting patients with ASD and ADHD

Prolonged stress and anxiety during pregnancy disrupting fetal brain development

A glimpse of dupilumab approval

Atopic dermatitis and infertility

WADA: Climate change is a public health crisis

FDA committee recommends Pfizer-BioNTech and Moderna COVID-19 vaccines for children 6 months and older

Reckitt Mead Johnson Receives FDA Approval to Import 66 Million Servings of Formula

WADA seeks to crack down on medical professionals spreading misinformation

An update on the presentation, nosology and causes of postpartum psychosis

Having “the conversation” with adolescent patients

]]>
The global medical laser market is expected to grow at a rate of 14% through 2026 https://parentsofallergicchildren.org/the-global-medical-laser-market-is-expected-to-grow-at-a-rate-of-14-through-2026/ Wed, 15 Jun 2022 12:19:00 +0000 https://parentsofallergicchildren.org/the-global-medical-laser-market-is-expected-to-grow-at-a-rate-of-14-through-2026/ Global Medical Lasers Market Report 2022 – Global Market Size, Trends and Forecast 2022-2026 The Business Research Company’s Global Medical Lasers Market Report Covers Market Drivers, Size, Key Players and Impact of COVID-19 on the Market LONDON, GREATER LONDON, United Kingdom, June 15, 2022 /EINPresswire.com/ — According to the “Medical Lasers Global Market Report 2022 […]]]>

Global Medical Lasers Market Report 2022 – Global Market Size, Trends and Forecast 2022-2026

The Business Research Company’s Global Medical Lasers Market Report Covers Market Drivers, Size, Key Players and Impact of COVID-19 on the Market

LONDON, GREATER LONDON, United Kingdom, June 15, 2022 /EINPresswire.com/ — According to the “Medical Lasers Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026” published by The Business Research Company, lasers Medical Devices market size is expected to reach USD 9.31 billion by 2026 at a CAGR of 13.7%. According to the global medical lasers market overview, the increased demand for minimally invasive procedures has contributed to the growth of the market over the period.

Want to learn more about the growth of the medical laser market? Request a sample now.
https://www.thebusinessresearchcompany.com/sample.aspx?id=3288&type=smp

The medical lasers market includes sales of medical lasers and related services by entities (organizations, individual traders, and partnerships) that manufacture medical lasers. Medical lasers are devices that treat or remove tissue using precisely focused light sources. Medical lasers find their applications in several surgical procedures, including eye surgery, cosmetic surgery, dental procedures, and other general procedures.

Global medical laser market trends
Medical laser market trends include major players focusing on developing new innovative products with advanced techniques to better serve healthcare professionals and their patients. For example, Lumenis Ltd., an energy-based medical device company based in Israel, introduced Legend Pro+, a new skin rejuvenation technology and unique multi-application platform powered by clinically proven technologies and complementary. Similarly, Ra Medical Systems, a US-based medical laser company, announced the launch of Pharos, a new dermatological excimer laser for the treatment of psoriasis, atopic dermatitis and vitiligo. Pharos provides improved comfort and visibility of the treatment site and is designed to enhance the physician and patient experience.

Segments of the global medical laser market
The global medical laser market is segmented:
By Product Type: Solid State Laser Systems, Gas Laser Systems, Dye Laser Systems, Diode Laser Systems
By application: Surgery, Cosmetics, Dental
By end use: ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular, others
By Geography: The global medical laser market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Of these regions, North America accounts for the largest share.

Learn more about the Global Medical Lasers Market report here
https://www.thebusinessresearchcompany.com/report/medical-lasers-global-market-report

The Global Medical Lasers Market Report 2022 is part of a series of new reports from The Business Research Company that provides Medical Lasers market overviews, analysis and forecasts of market size and growth for the Global Medical Lasers Market, Global Medical Lasers Market Share, Medical Lasers Market Segments and Geographies, Global Medical Lasers Market Players, Revenues, Profiles and Market Shares of Key Competitors in the Global Medical Lasers Market . The Medical Lasers Market report identifies key countries and segments for opportunities and strategies based on market trends and key competitor approaches.

The TBRC Global Medical Lasers Market 2022 report includes information on the following:

Data segmentation: market size, global, by region and country, historical and forecast, and growth rate for 60 geographies

Main market players: El.En. SpA, Ellex Medical Lasers Ltd, Lumenis, Alcon Laboratories Inc, AngioDynamics Corp, American Medical Systems Inc, Biolase Inc, Bausch & Lomb Holdings, Cardiogenesis Corporation Inc and Boston Scientific.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, United States, South America, Middle East and Africa.

Country: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And more.

Looking for something else? Here is a list of similar reports from the trade research company:

Global Medical Laboratory and Diagnostic Services Market Report 2022 – By Type (Diagnostic Imaging Centers, Medical Laboratory Services), By Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology), By Gender End User (Male, Female), by Type of Spend (Public, Private) – Global Market Size, Trends & Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market

Global Cardiovascular Medical Lasers Market Report 2022 – By Type (Excimer Laser, Carbon Dioxide Laser), By Application (Laser Vascular Anastomosis, Transmyocardial Laser Revascularization, Laser Angioplasty for Peripheral Arterial Diseases), By Use Final (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) – Market Size, Trends and Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Global Dental Medical Lasers Market Report 2022 – By Product (Soft Tissue, All Tissue, Dental Welding Lasers), By End User (Hospitals, Dental Clinics), By Application (Conservative Dentistry, Endodontic Treatment, Oral Surgery, Implantology , Peri-Implantitis, Periodontics, Teeth Whitening) – Global Market Size, Trends and Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/dentistry-medical-lasers-global-market-report

About the business research company?
The Business Research Company has published over 1,000 industry reports covering over 2,500 market segments and 60 geographies. The reports are based on 150,000 datasets, extensive secondary research and proprietary insights from interviews with industry leaders. Reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Discover our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Olivier Guirdham
The Business Research Company
+44 20 7193 0708
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Market Research Products, Services and Solutions for Your Business – TBRC

]]>
How to choose the best moisturizer to treat eczema in children https://parentsofallergicchildren.org/how-to-choose-the-best-moisturizer-to-treat-eczema-in-children/ Mon, 13 Jun 2022 21:36:00 +0000 https://parentsofallergicchildren.org/how-to-choose-the-best-moisturizer-to-treat-eczema-in-children/ BOSTON — Millions of children suffer from eczema and a mainstay of treatment is moisturizers, but which type is best? Eczema or atopic dermatitis is a chronic disease characterized by itchy scaly patches on the skin. It affects up to 20% of children. Parents are often advised to keep their child’s skin well moisturized to […]]]>

BOSTON — Millions of children suffer from eczema and a mainstay of treatment is moisturizers, but which type is best?

Eczema or atopic dermatitis is a chronic disease characterized by itchy scaly patches on the skin. It affects up to 20% of children.

Parents are often advised to keep their child’s skin well moisturized to avoid flare-ups, but families often want to know which product is best. So researchers in the UK asked carers of 550 children aged 12 and under with eczema to apply one of four types of moisturizers – creams, lotions, ointments or gels.

They found that none of them seemed more effective than the others.

That said, some providers believe, for example, that ointments work best on hands and feet, while creams or lotions work best on the face.

But at the end of the day, most experts agree that the best product is the one the child prefers and is most likely to use.

]]>
Acne breakouts can be made worse by climate change https://parentsofallergicchildren.org/acne-breakouts-can-be-made-worse-by-climate-change/ Sun, 12 Jun 2022 04:55:36 +0000 https://parentsofallergicchildren.org/acne-breakouts-can-be-made-worse-by-climate-change/ Cumulative data from recent years suggests that the burning of fossil fuels not only results in significant environmental impacts, but also significant overall and skin health impacts.1 While its negative impact on environmental health is clear, the effects that burning fossil fuels and a warming world have on skin diseases, including acne, have only more […]]]>

Cumulative data from recent years suggests that the burning of fossil fuels not only results in significant environmental impacts, but also significant overall and skin health impacts.1 While its negative impact on environmental health is clear, the effects that burning fossil fuels and a warming world have on skin diseases, including acne, have only more recently been explored.1

Markus D. Boos, MD, PhD, and colleagues, who published a recent article in the International Journal of Dermatologynoted that there is “clear evidence” that changes in certain climate variables – such as air pollution, humidity, temperature and ultraviolet (UV) radiation – not only affect distinct skin disorders, but also have direct effects on the skin microbiome.1 Additionally, these climatic factors appear to “influence each other’s severity” and have differential effects on the skin microbiome, creating complexities in how they can potentially be addressed, Boos said. Dermatology time®.

Boos, an attending pediatric dermatologist at Seattle Children’s Hospital and an associate professor in the Department of Pediatrics at the University of Washington School of Medicine, also in Seattle, with a small research team, reviewed the available literature on the effects of changes in climatic variables on the skin microbiome.

Based on this review, Boos noted that there are several established links between skin health and the burning of fossil fuels and climate change. “But the question with that [research] project was to dig a little deeper and ask if there is an intermediate link between climate variables and skin diseases that we don’t consider,” he explained. “Something could be a risk factor for what we see manifesting in the skin, but what we want to know is whether what we see could be mediated by changes in the skin microbiome.”

Climatic variables and skin microbiome: what is the link?

Stratospheric ozone depletion — due to the use of chlorofluorocarbons and other compounds — has caused UV radiation levels to increase over the past few decades, Boos and his colleagues explained in their paper. The chemicals, which function as potent greenhouse gases, increase effective surface levels of UV radiation and therefore have critical implications for skin health.

Boos and researchers explained that several skin bacteria produce antioxidants that prevent UV-induced carcinogenesis. Specifically, the investigators cite data from a mouse model that show that some Staphylococcus epidermidis strain can suppress UV-induced tumor growth. Although potentially protective, Boos and his colleagues noted that skin bacteria may be more vulnerable to higher effective doses of UV radiation at high temperatures, which are direct consequences of climate change.

For acne, changes in temperature and increased UV radiation are correlated with disease flare-ups. Specifically, the researchers cite evidence that warmer temperatures increase sebum levels, humidity increases swelling of the pilosebaceous unit, and UV radiation leads to hyperplasia of the sebaceous glands, thus promoting the growth of sebaceous glands. Cutibacterium acnes.1 Although these changes may depend on each patient’s microbiome, they could increase C. acnes and lead to persistent inflammation and the precipitation of acne breakouts “in the absence of other competing microbes,” the researchers explained.

Addressing knowledge gaps

Despite the significant association between climate change and skin health, there are still critical knowledge gaps regarding this association and its relationship to driving or worsening skin disease. “If increased UV radiation puts you at risk for skin cancer, but it also has effects on other diseases such as atopic dermatitis or psoriasis, then we need to think about the presence of another element in this association,” explained Boos.

Part of the problem with developing solutions to climate change and its effects on skin health is the multivariate nature of the problem, Boos explained. “And all of these variables influence each other,” he said.

For example, Boos added that for every 1 degree centigrade increase in temperature, the effective UV dose increases by 2%. “So even something as simple as UV radiation varies with temperature and how that consequently affects your skin,” he said.

According to the researchers, the use of 3-dimensional (3D) human skin models in vitro could be useful for studying the skin microbiome in relation to climate change. With 3D skin models, Boos explained, researchers can control all climate-related variables, including humidity, temperature, and bacterial species present on the skin at any given time.

Other research directions

One of the big questions, Boos says, is whether bacteria actually mediate climate variables and how those variables actually affect the skin. “This is an important question because for different conditions, like acne, people talk about the applicability of skin bacteria transplants as a treatment option,” he added.

But unless we stop burning fossil fuels and completely eliminate pollution, which is no easy task in today’s world, Boos suggested there is value in taking advantage of bacteria. on the skin to lessen the effects of the changing environment on dermatological results.

Further research is also needed to better understand how the environment alters the human microbiome, as this better understanding “holds promise for the treatment and prevention of skin diseases,” Boos and colleagues wrote in their paper.

Disclosures:

The study researchers reported no conflicts of interest with the pharmaceutical industry.

References:

1. Isler MF, Coates SJ, Boos MD. Climate change, skin microbiome and skin diseases: implications for a warming world [published online ahead of print, 2022 May 22]. Int J Dermatol. 2022;10.1111/ijd.16297. doi:10.1111/ijd.16297

]]>
Amytrx Therapeutic’s AMTX-100 CF3 Advances to Phase II Clinical Trial for Atopic Dermatitis https://parentsofallergicchildren.org/amytrx-therapeutics-amtx-100-cf3-advances-to-phase-ii-clinical-trial-for-atopic-dermatitis/ Thu, 09 Jun 2022 15:00:00 +0000 https://parentsofallergicchildren.org/amytrx-therapeutics-amtx-100-cf3-advances-to-phase-ii-clinical-trial-for-atopic-dermatitis/ We are encouraged by the biological impact on the patients of this study for their treatment. Tweet that Amytrx specializes in safe and effective anti-inflammatory peptide therapies for patients with chronic inflammatory and autoimmune diseases. AMTX-100 CF3, its lead drug candidate, is known for its ability to transport across membranes, treat inflammation and modulate immune-mediated […]]]>

Amytrx specializes in safe and effective anti-inflammatory peptide therapies for patients with chronic inflammatory and autoimmune diseases. AMTX-100 CF3, its lead drug candidate, is known for its ability to transport across membranes, treat inflammation and modulate immune-mediated diseases instead of just inhibiting inflammation.

“We are encouraged by the biological impact on the patients of this study for their treatment with a treatment that we believe is not only effective, but that promotes adherence,” said Randy Riggs, Commercial Director at Amytrx. “We are excited about the potential of our therapeutic peptide that does not inhibit, but safely modulates inflammation to drive resolution of immune-mediated diseases.”

Working together, Amytrx and Amarex successfully completed the drug’s exploratory Phase I safety and efficacy trial in humans in 2021. Amytrx is launching the Phase II trial in adult subjects with atopic dermatitis mild to moderate using transcriptomic mapping. The study will assess the safety and efficacy of the treatment over 28 days.

Amarex designed this study, submitted the IND application for FDA approval, diligently guided Amytrx through the Phase I trial, and is poised to continue to lead the product through the FDA trials until it is approved for the market.

“We are delighted that our expert solutions and dedicated staff helped Amytrx achieve this critical milestone on time.” says dr. Kazem Kazempur, President and CEO of Amarex. “The FDA has given us the green light to proceed with this adaptive design trial moving from Phase I, illustrating our commitment to helping sponsors accelerate their development of safe and innovative treatments for patients. Amarex is honored to work with Amytrx on their revolutionary anti-inflammatory treatment project. »

Based on the safety profile of AMTX-100 CF3 in Phase I/II, Amytrx plans to approach adolescent and juvenile subjects in its Phase II. Amytrx is actively pursuing the use of AMTX-100 in other indications and is collaborating with institutions on its leukocyte-targeted cell-penetrating peptide delivery platforms to address other unmet medical needs in the areas of inflammation, autoimmune diseases and cancer.

Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) offering the potential for highly optimized breakthrough therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treating some of the world’s most debilitating diseases. For more information, please visit www.amytrx.com.

Clinical Research Amarex, LLC (www.amarexcro.com), an NSF company, is a full-service global contract research organization (CRO), whose leadership has significant expertise in biomedical research. Their combined experience includes the design and conduct of several hundred clinical research projects in numerous therapeutic indications. Amarex provides project management services: Phase I-IV, BE/BA, PK/PD; regulatory affairs: FDA applications and meetings, applications to international health authorities, GxP compliance audits; clinical operations; adaptive study designs; statistical analysis, data management; medical supervision; safety and pharmacovigilance; and general consultation. Amarex can support your product through the approval process, from creating the regulatory approval strategy, to conducting trials, to writing the marketing approval request. Join our growing list of customers with trusted products backed by quality, cost-effective services. For more information, visit www.amarexcro.com.

NSF (nsf.org) is an independent, global organization that facilitates the development of standards and tests and certifies products for the food, water, health sciences and consumer goods industries to minimize harmful effects on health and protect the environment. Founded in 1944, NSF is committed to protecting human health and safety worldwide. Present in 180 countries, NSF is a Pan American Health Organization and World Health Organization (WHO) Collaborating Center on Food Safety, Water Quality and Indoor Environment.

NSF’s health science services include training and education, consulting, clinical research, regulatory guidance, corporate compliance, and separately auditing, GMP and GLP analytical testing, testing ADN, certification and R&D for the pharmaceutical biotechnology, medical device and dietary supplement industries. throughout the product life cycle.

SOURCE Amytrx Therapeutics

]]>
Doctors reveal tips for tackling skin allergies during the monsoon for radiant skin https://parentsofallergicchildren.org/doctors-reveal-tips-for-tackling-skin-allergies-during-the-monsoon-for-radiant-skin/ Sun, 05 Jun 2022 11:26:10 +0000 https://parentsofallergicchildren.org/doctors-reveal-tips-for-tackling-skin-allergies-during-the-monsoon-for-radiant-skin/ The monsoons are a welcome relief from the summer heat, but even if the temperature drops a few degrees, the humidity and humidity can cause various allergies and itchy skin infections and health experts warn that eczema like Atopic dermatitis and seborrheic dermatitis can erupt during monsoons. due to weather changes and humidity disrupting the […]]]>

The monsoons are a welcome relief from the summer heat, but even if the temperature drops a few degrees, the humidity and humidity can cause various allergies and itchy skin infections and health experts warn that eczema like Atopic dermatitis and seborrheic dermatitis can erupt during monsoons. due to weather changes and humidity disrupting the skin barrier, making it vulnerable to external contaminants. While dancing in the rain can be a lot of fun, the torrential downpour season is a surefire recipe for vague allergies.

The combination of heat and humidity during the monsoon causes itchy skin or rashes resulting in rapid bacterial growth caused by sweating and this easily occurs in areas with creases such as the back of the knees, inside of the elbows, the space between the toes or fingers. and intimate areas. Monsoons also present a real risk of causing mold in places like walls, cabinets or any open surface with direct moisture and more are exposed to dampness which can be a cause of illnesses like sneezing, coughing , eye infection, inflammation, congestion, headaches and rashes common in this climate.

In an interview with HT Lifestyle, Dr. Yuti Nakhwa, Consultant Dermatologist and Cosmetologist at Global Hospital, Parel Mumbai, revealed, “During the monsoon season, excessive humidity in the atmosphere leads to high moisture retention. on the skin, which causes an increase in infections such as fungus. infections on the body. Therefore, one should keep the skin dry, avoid very tight clothes or jeans. Instead, go for loose, lightweight cotton clothes, which would really come in handy.”

She added, “When it comes to the face, too much moisture can increase sweating and the face becomes very greasy. Therefore, to keep the skin clean, use a mild cleanser that will take care of their skin and remove the excess oil and sweat.Which will keep the skin clean and healthy without drying out the skin.Even though it may be cloudy and rainy, don’t forget your sunscreen and moisturize your skin very well using moisturizer Also, sometimes we see an increase in eczema on the skin, so hydration is very important for this.

According to Dr. Raashi Mehta, Consultant Dermatologist at Masina Hospital, Mumbai, bath daily with lukewarm water and mild soap/body wash, avoid perfumes, oatmeal pads and use light moisturizer containing emollients such as liquid paraffin, shea butter, etc. and humectant like glycerin or dimethicone can help lock in skin’s moisture and prevent water loss. Fungal infections such as athlete’s foot and ringworm also increase during monsoons due to humidity and sweat buildup, especially in skin folds. This leads to sometimes uncontrollable itching and the formation of a red ring like rash. Wearing loose, light-colored clothing, taking showers twice a day, and using absorbent powders can help prevent infection, but a visit to a dermatologist is essential for proper treatment.

Due to the increased population of insects during monsoons, especially mosquitoes, allergic reactions mimicking hives through insect bites, increase dramatically during monsoons, especially in young children. Dr Raashi Mehta advised, “Covering exposed areas of the body, applying repellents and sleeping in mosquito nets helps prevent such allergies. Also due to food contamination and increased viral infections, allergies and skin urticaria are commonly seen. Eating home cooked food and avoiding crowded places helps prevent such infections.

Dr Banani Choudhury, Consultant Dermatologist, Sir HN Reliance Foundation Hospital, said: “The monsoons are particularly harsh on people with oily skin. This type of skin can experience an outbreak of red, raised bumps. It is common to have watery eyes that itch and become too dry, as well as painful. The season promotes the growth of bacteria on blackheads, turning them into inflamed acne in their own right. During the monsoons in particular one tends to get skin allergies and fungal infections in the coverings like armpits, groins and buttocks and it is important to see a dermatologist to treat these as this can lead to chronic infections.

She recommended: “For the face, use a gentle yet effective medical grade cleanser and avoid touching your face at all times. Wear minimal makeup and avoid using heavy hair products as they allow germs to easily stick to your skin causing infections or various bacteria. Wear loose, breathable clothing and always take a hot shower when you get home, then apply powder to your body. The monsoon season is an excellent time to use a dehumidifier to remove humidity from the home. Also, use cotton bedding and replace it every few days. In this season, using a micellar water on the face in the form of a spray or lotion twice a day helps to remove the sticky feeling on the face and reduce oiliness. Glycolic/salicylic acid facial wipes can also be used once daily to serve the same purpose.

]]>
PRP and PRF in Cosmetics Market to Register CAGR of 12.6% from 2021 to 2031, TMR Study https://parentsofallergicchildren.org/prp-and-prf-in-cosmetics-market-to-register-cagr-of-12-6-from-2021-to-2031-tmr-study/ Fri, 03 Jun 2022 12:30:00 +0000 https://parentsofallergicchildren.org/prp-and-prf-in-cosmetics-market-to-register-cagr-of-12-6-from-2021-to-2031-tmr-study/ Substantial spending on cosmetic procedures by the middle-aged and elderly population for a youthful look is fueling the demand for PRP and PRF in cosmetic treatments Growing economic prosperity and growing availability of advanced beauty treatments are fueling the growth of PRP and PRF in the cosmetics market in developing countries ALBANY, NY, June 3, […]]]>
  • Substantial spending on cosmetic procedures by the middle-aged and elderly population for a youthful look is fueling the demand for PRP and PRF in cosmetic treatments
  • Growing economic prosperity and growing availability of advanced beauty treatments are fueling the growth of PRP and PRF in the cosmetics market in developing countries

ALBANY, NY, June 3, 2022 /PRNewswire/ — PRP and PRF in the cosmetics market are estimated to exceed a valuation of US$150 million by 2031. Substantial increase in expenditure for skin rejuvenation therapies creates opportunities in PRF and PRP in cosmetics market. Rising economic prosperity and growing self-care awareness among individuals of all age groups is fueling the demand for PRF and PRP in cosmetic procedures in emerging economies.

The attractive results of PRP and PRF in cosmetic treatments in terms of improved skin volume, tone and texture, and reduced appearance of wrinkles are a few important factors for their growing popularity.

The demand analysis of the PRP and PRF cosmetics market reveals that the middle-aged population and the elderly show the major demand for plastic surgeries. According to the International Society for Aesthetic Plastic Surgery, in 2020, approximately 10,129,529 cosmetic procedures were performed worldwide, including 1,601,713 breast augmentation procedures, 1,300,020 liposuction procedures, and 968,381 eyelid surgeries.

Request Brochure on PRP and PRF in Cosmetics Market Research Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=84811

PRP and PRF in Cosmetics Market – Key Findings of the Report

  • The future prospects of PRP and PRP in the cosmetics market are promising with high potential of PRP and PRF in cosmetic treatments. PPR therapy is an effective substitute for hyaluronic acid and can be used as a dermal filler to help wounds heal quickly.
  • The demand for platelet-rich plasma therapy is increasing due to its effectiveness in facial therapy, oral-maxillofacial surgery, treating wrinkles, and increasing soft tissue repair.
  • Key players of PRP and PRF in the cosmetics market are considering capacity expansion to meet the predicted increase in demand for different types of cosmetic applications such as PRF for facial rejuvenation
  • Small and large biopharmaceutical companies that offer PRP and PRF in cosmetic procedures are increasingly outsourcing R&D to contract research organizations (CROs) and other clinical service specialists for continuous improvement.
  • The pure-PRP segment held nearly 61% market share for PRP and PRF in cosmetics in 2021. The segment is expected to continue to hold a key share of PRP and PRF in cosmetics market in the coming years. The demand for pure PRP stems from technological advances leading to its various applications as well as its richness in platelets. This, together with concentrations of pure PRP segment growth factors, promotes skin rejuvenation.
  • The efficacy of autologous PRP and PRF products in regenerative medicine and the recognition of platelet-rich plasma (PRP) as a key source of autologous products for regenerative medicine is gaining momentum
  • Developed economies such as the United States and countries in the Europe account for a substantial share of PRP and PRF in the cosmetics market.
  • North America held the largest revenue share of PRP and PRF in the cosmetics market in 2021. New product approvals, technological advancements and increasing applications of PRP in cosmetic surgeries are fueling the growth of PRP and PRF in the region’s cosmetics market.

Demand for Analysis of Impact of COVID-19 on PRP and PRF in Cosmetics Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=84811

PRP and PRF in Cosmetics Market – Growth Drivers

  • The attractive results of PRP and PRF therapy for cosmetic treatments, including skin rejuvenation, wrinkle reduction, skin tightening, acne scar reduction, complexion improvement and blemish removal. deep creases fuel the growth of PRP and PRF in the cosmetics market
  • Strong volume demand for cosmetic surgeries including breast augmentation, eyelid and liposuction procedures cements the growth of PRP and PRP in the cosmetics market

Get Exclusive Sample PDF Copy of PRP and PRF in Cosmetics Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=84811

PRP and PRF in Cosmetics Market – Key Players

Some of the major players operating in PRP and PRF in cosmetics market are;

  • Stryker Company
  • Zimmer Biomet
  • Exactech Inc.
  • EmCyte Corporation
  • Regeneration Lab
  • APEX Biologix
  • ThermoGenesis Holdings Inc.
  • Isto Biologics

Inquire Before You Buy – https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=84811

The PRP and PRF in cosmetics market is segmented as follows;

PRP and PRF in Cosmetics Market, by Type

  • Pure-PRP
  • Pure-PRF
  • leukocyte PRP

PRP and PRF in the cosmetics market, by origin

  • Autologous
  • Counterpart
  • allogenic
  • Others

PRP and PRF in the Cosmetics Market, by Application

  • Skin rejuvenation
  • Hair Application
  • Treatment related to scars
  • face lift
  • Plastic surgery
  • Others

PRP and PRF in Cosmetics Market, by Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Modernization of healthcare in terms of infrastructure and services has pushed the healthcare industry to new heights, stay updated with Health Care Research Reports by Transparency Market Research:

Skin Care Devices Market: Rising incidence of skin disorders such as acne, atopic dermatitis, psoriasis, rosacea and skin cancer is expected to drive the global skin care devices market the skin during the forecast period. Rising geriatric population, increasing incidence of skin disorders and high adoption of advanced products and techniques are expected to fuel the growth of the North America skincare device market.

Platelet Rich Plasma Market: Platelet Rich Plasma has been valued at US$815.3 million in 2020 and is expected to grow at a CAGR of 11.2% from 2021 to 2031. Plasma is found in the blood, which contains factors such as proteins that support cell growth.

Plasma Foods Market: Plasma Foods Market is driven by increasing meat production globally, demand for protein-rich animal meal, adoption of pets, humanization contributing to the demand for protein-rich pet food, pet food production and industrial plasma food applications.

Venous Skin Ulcer Treatment Market: High post-healing recurrence rates have catalyzed the demand for compression hosiery products in the venous skin ulcer treatment market. This is evident as the revenue of compression therapy products is expected to grow aggressively in the venous skin ulcer treatment market.

About Us

Transparency Market Research is a global market information company that provides market research reports and services. Our proprietary blend of quantitative forecasting and trend analysis provides forward-looking insights to thousands of decision makers. Our experienced team of analysts, researchers and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With broad research and analytical capability, Transparency Market Research uses rigorous primary and secondary research techniques to develop distinctive datasets and research material for trade reports.

For more information on research on leading industries, visit our YouTube channel and click subscribe for future update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey

Transparency Market Research Inc.
HEADQUARTERS IN THE CITY CENTER,
1000 N. West Street,
Office 1200,
Wilmington, Delaware 19801 United States

UNITED STATES – Canada Toll Free: 866-552-3453
E-mail: [email protected]
Follow us: Twitter | LinkedIn Blog: https://tmrblog.com

SOURCE Transparency Market Research

]]>
Sanofi Form 6-K Due: May 31 https://parentsofallergicchildren.org/sanofi-form-6-k-due-may-31/ Tue, 31 May 2022 14:57:12 +0000 https://parentsofallergicchildren.org/sanofi-form-6-k-due-may-31/ Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potentials of the product, or regarding the potential future revenues of the product. […]]]>

Sanofi forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potentials of the product, or regarding the potential future revenues of the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include, among others, unexpected regulatory actions or delays, or government regulation generally, which could affect the availability or commercial potential of the product, the product’s failure to achieve commercial success, uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post-marketing, unexpected safety, quality or manufacturing issues, competition in general , risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19[feminine] will have on us, our customers, suppliers, vendors and other business partners, and the financial condition of each of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19[feminine] on any of these elements could also have a negative impact on us. This situation is changing rapidly and additional impacts may arise that we are not currently aware of and may exacerbate other previously identified risks. Risks and uncertainties also include uncertainties discussed or identified in public filings with the SEC and AMF by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements”. in Sanofi’s annual report on the form 20-F for the year ended December 31, 2021. Except as required by applicable law, Sanofi undertakes no obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements and Use of Digital Media

This press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially. of these forward-looking statements. research statements. Words such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “seek”, “estimate”, variations of these words and similar expressions are intended to identify these forward-looking statements, although not all forward-looking statements contain these identifying words. These statements relate to, and such risks and uncertainties include, but are not limited to, the impact of SARS-CoV-2 (the virus that caused the COVID-19[feminine] pandemic) on the operations of Regeneron and its employees, collaborators, suppliers and other third parties upon which Regeneron relies, the ability of Regeneron and its collaborators to continue to conduct research and clinical programs, the ability of Regeneron to manage its supply chain, net sales of products marketed or otherwise marketed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron Products”) and the global economy; the nature, timing, possible success and therapeutic applications of Regeneron’s products and product candidates developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s product candidates”) and research programs and ongoing or planned clinics, including but not limited to Dupixent® (dupilumab) for the treatment of nodular prurigo; the likelihood, timing and scope of eventual regulatory approval and commercial launch of Regeneron’s product candidates and new indications for Regeneron’s products, such as Dupixent for the treatment of prurigo nodularis (including approval by the United States Food and Drug Administration based on the Biologics Supplement License Application discussed in this press release), pediatric atopic dermatitis, atopic dermatitis of the hands and feet, chronic obstructive pulmonary disease with signs of inflammation of type 2, pediatric eosinophilic esophagitis, bullous pemphigoid, chronic spontaneous urticaria, chronic pruritus of unknown origin, chronic inducible urticaria – common cold, chronic rhinosinusitis without nasal polyposis, allergic fungal rhinosinusitis, allergic bronchopulmonary aspergillosis and other potential indications; uncertainty regarding the use, market acceptance and commercial success of Regeneron’s products (such as Dupixent) and Regeneron’s product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandatory or voluntary), including studies discussed or referenced in this press release, any of the foregoing or any potential regulatory approval of Regeneron’s products (such as Dupixent) and Regeneron’s product candidates. Regenerate; the ability of Regeneron’s collaborators, licensees, suppliers or other third parties (as applicable) to perform the manufacturing, filling, finishing, packaging, labeling, distribution and other steps related to the products of Regeneron and Regeneron’s product candidates; Regeneron’s ability to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron’s products (such as Dupixent) and Regeneron’s product candidates in patients, including serious complications or side effects related to the use of Regeneron’s products and product candidates of Regeneron in clinical trials; decisions of governmental regulatory and administrative authorities that may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron Products and Regeneron Product Candidates, including, without limitation, Dupixent; ongoing regulatory obligations and oversight impacting Regeneron’s products, research and clinical programs and operations, including those relating to patient privacy; the availability and extent of reimbursement for Regeneron’s products from third-party payers, including private healthcare and insurance programs, health maintenance organizations, drug benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior or more cost-effective than Regeneron’s products and Regeneron’s product candidates; the extent to which the results of research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to the advancement of product candidates into clinical trials, applications therapeutics or regulatory approval; unforeseen expenses; product development, production and selling costs; Regeneron’s ability to meet any of its financial projections or guidance and changes to assumptions underlying such projections or guidance; the possibility that any license, collaboration or supply agreement, including Regeneron’s agreements with Sanofi, Bayer and Teva Pharmaceutical Industries Ltd. (or their respective affiliates, as applicable) be canceled or terminated; and risks associated with the intellectual property of other parties and pending or future litigation relating thereto (including, without limitation, patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent, Praluent® (alirocumab), and REGEN-VOC® (casirivimab and imdevimab)), other litigation and other government proceedings and investigations relating to the Company and/or its operations, the ultimate outcome of such proceedings and investigations, and the impact any of the above may have on business, outlook, results of operations and financial condition. A more complete description of these and other material risks may be found in Regeneron’s filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021 and its Form 10-Q for the quarterly period ended March 31, 2022. All forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron undertakes no obligation to update (publicly or otherwise) any forward-looking statements, including, without limitation, any financial projections or guidance, whether as a result of new information, future events or otherwise. .

Regeneron uses its media and investor relations website and social media to post material information about the Company, including information that may be considered material to investors. Financial and other information about Regeneron is published regularly and can be accessed on Regeneron’s Media and Investor Relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com /regenerate).

3/3

]]>
Connect Biopharma Holdings Limited (NASDAQ:CNTB) Brief Update on Interests https://parentsofallergicchildren.org/connect-biopharma-holdings-limited-nasdaqcntb-brief-update-on-interests/ Sun, 29 May 2022 20:29:07 +0000 https://parentsofallergicchildren.org/connect-biopharma-holdings-limited-nasdaqcntb-brief-update-on-interests/ Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) was the target of a sharp decline in short-term interest in May. As of May 15, there was short interest totaling 183,100 shares, down 42.5% from the April 30 total of 318,400 shares. Based on an average daily trading volume of 244,800 shares, the day-to-cover ratio is […]]]>

Connect Biopharma Holdings Limited (NASDAQ:CNTB – Get Rating) was the target of a sharp decline in short-term interest in May. As of May 15, there was short interest totaling 183,100 shares, down 42.5% from the April 30 total of 318,400 shares. Based on an average daily trading volume of 244,800 shares, the day-to-cover ratio is currently 0.7 days.

A number of equity research analysts have weighed in on CNTB shares. Zacks Investment Research downgraded Connect Biopharma from a “buy” rating to a “hold” rating in a Wednesday, April 6 research report. Piper Sandler downgraded Connect Biopharma from an “overweight” rating to a “neutral” rating in a Thursday, May 5 research report. Finally, SVB Leerink began covering Connect Biopharma in a research report on Friday, April 1. They issued a “buy” rating and a target price of $22.00 for the company.

NASDAQ:CNTB shares rose $0.04 on Friday, hitting $0.85. 90,993 shares of the company were traded, with an average volume of 658,303. Connect Biopharma has a fifty-two week low of $0.56 and a fifty-two week high of $29.27. The company’s 50-day moving average is $2.11 and its 200-day moving average is $4.01.

Several large investors have recently changed their positions in the CNTB. Janus Henderson Group PLC increased its equity stake in Connect Biopharma by 3.1% in the third quarter. Janus Henderson Group PLC now owns 403,459 shares of the company valued at $9,567,000 after buying an additional 12,120 shares last quarter. Vident Investment Advisory LLC purchased a new stake in shares of Connect Biopharma in the third quarter at a value of $263,000. Goldman Sachs Group Inc. purchased a new equity stake in Connect Biopharma in the fourth quarter at a value of $61,000. Renaissance Technologies LLC purchased a new stake in shares of Connect Biopharma in the fourth quarter at a value of $56,000. Finally, Kynam Capital Management LP acquired a new position in shares of Connect Biopharma in the first quarter at a value of $688,000. Institutional investors hold 34.21% of the company’s shares.

About Connect Biopharma (Get an assessment)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The Company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in a Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.

Further reading



Get news and reviews for Connect Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Connect Biopharma and related companies with MarketBeat.com’s free daily email newsletter.

]]>